ASBRS Great Debate: Sentinel Node Biopsy in Patients Over 70 Years of Age.

Mednet Member

Surgical Oncology · Duke University Medical Center

It is clear that we are moving away from aggressive axillary surgery for patients with minimal axillary disease given that no survival or axillary recurrence benefit (ACOSOG Z11, AMAROS) and increased risks of functional morbidities have been identified with completion axillary dissection. Naturally...